ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

About this update from Alx Oncology Holdings Inc.

SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that management will participate in the Jefferies 2025 Global Healthcare Conference. Details are as follows: Format: Fireside Chat Date: Thursday, June 5, 2025 Time: 1:25 PM ET Location: New York, NY Webcast link: Available  here The live webcast of the Jefferies fireside chat can be accessed by visiting the Investors section of ALX Oncology’s website at  www.alxoncology.com under the Events  section of the Events and Presentations tab. A replay of the webcast will be archived for up to 90 days following the fireside chat date. About ALX Oncology ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action and is anticipated to enter Phase 1 trials mid-2025. More information is available at  www.alxoncology.com  and on LinkedIn  @ALX Oncology . Investor Relations Contact: Elhan Webb, CFA, IR Consultant [email protected] Media Contact: Audra Friis, Sam Brown Healthcare Communications [email protected] (917) 519-9577

View stock analysis, news, and events for Alx Oncology Holdings Inc.